NASDAQ
Kaleido Biosciences, Inc. (KLDO) has a price/sales ratio of 90.62x as of Friday, May 22, 2026. This represents a 16.11% increase compared to its 12-month average of 78.05x. The price-to-sales ratio evaluates a company's stock price relative to its revenue, useful for valuing companies with little or no earnings.
No price data available for this timeframe.